Xencor Inc (XNCR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xencor Inc (XNCR) has a cash flow conversion efficiency ratio of -0.049x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.82 Million) by net assets ($625.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XNCR company net worth for the company's overall valuation and market capitalisation.
Xencor Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Xencor Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xencor Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xencor Inc ranked by their cash flow conversion efficiency. Explore how high is Xencor Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
0.034x |
|
Vulcabras Azaleia S.A
SA:VULC3
|
0.055x |
|
Abacus Life Inc.
NASDAQ:ABL
|
-0.075x |
|
Anhui Sierte Fertilizer Industry Ltd Co
SHE:002538
|
0.024x |
|
Guangdong Guanhao High-Tech Co Ltd
SHG:600433
|
-0.001x |
|
One United Properties SA
RO:ONE
|
-0.037x |
|
Zhejiang Whwh
SHG:600576
|
0.061x |
|
XiAn ChenXi Aviation Technology Corp Ltd
SHE:300581
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Xencor Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Xencor Inc from 2011 to 2024. View current stock price of Xencor Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $674.03 Million | $-202.19 Million | -0.300x | -335.83% |
| 2023-12-31 | $669.13 Million | $85.11 Million | 0.127x | +277.92% |
| 2022-12-31 | $727.50 Million | $24.48 Million | 0.034x | +246.49% |
| 2021-12-31 | $733.50 Million | $-16.85 Million | -0.023x | -162.84% |
| 2020-12-31 | $572.44 Million | $-5.00 Million | -0.009x | -108.06% |
| 2019-12-31 | $593.20 Million | $64.37 Million | 0.109x | +170.98% |
| 2018-12-31 | $521.68 Million | $-79.76 Million | -0.153x | -28.02% |
| 2017-12-31 | $282.05 Million | $-33.68 Million | -0.119x | -139.63% |
| 2016-12-31 | $313.95 Million | $94.62 Million | 0.301x | +83.58% |
| 2015-12-31 | $162.43 Million | $26.67 Million | 0.164x | +145.59% |
| 2014-12-31 | $59.29 Million | $-21.35 Million | -0.360x | -385.61% |
| 2013-12-31 | $73.53 Million | $-5.45 Million | -0.074x | -113.09% |
| 2012-12-31 | $-19.50 Million | $-11.05 Million | 0.567x | +471.26% |
| 2011-12-31 | $-10.94 Million | $-1.08 Million | 0.099x | -- |
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more